Brief: Relief Therapeutics And Acer Therapeutics Issue U.S. Patent 11,154,521 Covering ACER-001 Formulation
26/10/2021 06:14
Oct 26 (Reuters) - RELIEF THERAPEUTICS HOLDING SA RLFB.S :
* ACER THERAPEUTICS AND RELIEF THERAPEUTICS ANNOUNCE
ISSUANCE OF
U.S. PATENT 11,154,521 COVERING ACER-001 FORMULATION
* PATENT 11,154,521 COVERS PHARMACEUTICAL COMPOSITION CLAIMS
RELATED TO ACER-001'S TASTE-MASKED, MULTI-PARTICULATE DOSAGE
FORMULATION FOR ORAL ADMINISTRATION
* NEWLY ISSUED PATENT HAS AN EXPIRATION DATE IN 2036
Source text for Eikon: ID:nEQ2Sk5Qya
Further company coverage: RLFB.S
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 6600;))
Recent news on Acer Therapeutics
See all newsBrief: Leading Independent Proxy Advisory Firms Iss And Glass Lewis Recommend Acer Therapeutics Shareholders Vote "For" The Proposed Merger And Related Proposals
U.S. STOCKS ON THE MOVE-UGI, SkyWest, Sage Therapeutics
Acer Therapeutics surges on Zevra buyout deal
Brief: Zevra Therapeutics To Acquire Acer Therapeutics, Expanding Its Rare Disease Portfolio And Adding Commercial Product
Swiss stocks - Factors to watch on August 31